REFERENCES
  1. Steiner al, goodman ad, powers sr. Study of a kindred with pheochromocytoma, medullary thyroid carcinoma, hyperparathyroidism and gushing’s disease: multiple endocrine neoplasia, type 2. Medicine. 1968 Sep 1;47(5):371-409.
  2. Melvin KEW, Tashjian Jr AH, Miller HH 1972 Studies in familial (medullary) thyroid carcinoma. Recent Prog Horm Res 28:399 – 470
  3. Gagel RF, Tashjian Jr AH, Cummings T, Papathanasopoulos N, Kaplan MM, DeLellis RA, Wolfe HJ, Reichlin S. The clinical outcome of prospective screening for multiple endocrine neoplasia type 2a. New England Journal of Medicine. 1988 Feb 25;318(8):478-84.
  4. Schuffenecker I, Virally-Monod M, Brohet R, Goldgar D, Conte-Devolx B, Leclerc L, Chabre O, Boneu A, Caron J, Houdent C, Modigliani E. Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutations at codon 634 of the RET proto-oncogene. The Journal of Clinical Endocrinology & Metabolism. 1998 Feb 1;83(2):487-91.
  5. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, Van Amstel HK, Lips CJ, Nishisho I, Takai SI, Marsh DJ. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2: International RET Mutation Consortium analysis. Jama. 1996 Nov 20;276(19):1575-9.
  6. Ponder BAJ 2001 Multiple endocrine neoplasia type 2. In: Scriver CR Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular bases of inherited disease, 8th Ed. New York: McGraw-Hill; 931–942
  7. Ghosh A, Nundy S, Mallick TK. How India is dealing with COVID-19 pandemic. Sensors International. 2020 Jan 1;1:100021.
  8. Gild M, Clifton-Bligh R, Robinson BG. Multiple Endocrine Neoplasia Type 2 and Bone. InGenetics of Bone Biology and Skeletal Disease 2013 Jan 1 (pp. 505-513). Academic Press.
  9. Mannelli M, Bemporad D. Diagnosis and management of pheochromocytoma during pregnancy. Journal of endocrinological investigation. 2002 Jun;25(6):567-71.
  10. Alexander EK, Pearce EN, Brent GA, Brown RS, Chen H, Dosiou C, Grobman WA, Laurberg P, Lazarus JH, Mandel SJ, Peeters RP. 2017 Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. Thyroid. 2017 Mar 1;27(3):315-89.
  11. Wells Jr SA, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, Lee N, Machens A, Moley JF, Pacini F, Raue F. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma: the American Thyroid Association Guidelines Task Force on medullary thyroid carcinoma. Thyroid. 2015 Jun 1;25(6):567-610.
  12. Silva OL, Titus-Dillon P, Becker KL, Snider RH, Moore CF. Increased serum calcitonin in pregnancy. Journal of the National Medical Association. 1981 Jul;73(7):649.
  13. Tewari KS, Steiger RM, Lam ML, Rutgers JK, Berkson RA, DiSaia PJ. Bilateral pheochromocytoma in pregnancy heralding multiple endocrine neoplasia syndrome IIA. A case report. The Journal of reproductive medicine. 2001 Apr 1;46(4):385-8.
  14. Sarathi V, Bandgar TR, Menon PS, Shah NS. Pheochromocytoma and medullary thyroid carcinoma in a pregnant multiple endocrine neoplasia-2A patient. Gynecological Endocrinology. 2011 Aug 1;27(8):533-5.
  15. Donatini G, Kraimps JL, Caillard C, Mirallié E, Pierre F, De Calan L, Hamy A, Larin O, Tovkay O, Cherenko S. Pheochromocytoma diagnosed during pregnancy: lessons learned from a series of ten patients. Surgical endoscopy. 2018 Sep;32(9):3890-900.
Table S1: Investigations for pheochromocytoma, MTC and hyperparathyroidism as part of MEN 2A syndrome